Mirugen – Unlocking the Power of Retina Regeneration
Mirugen – Unlocking the Power of Retina Regeneration
Search
Search results
SB-007, we’ve been expecting you
Introducing Splice Bio, a genetic medicines company with some exciting developments for Stargardt’s patients.
Medical research
Retina UK has invested more than £16million into cutting-edge research since the charity was founded in 1976.
Autoimmune Retinopathy
Autoimmune diseases are quite distinct from inherited retinal dystrophies.
Types of genetic testing
This page explains the different types of genetic tests: diagnostic testing, predictive testing, carrier testing and research testing
Opus genetics launches clinical trial for MERTK-related retinitis pigmentosa
Opus Genetics has launched an early-stage clinical trial of OPGx-MERTK, an investigational gene therapy for MERTK-related Retinitis Pigmentosa (RP), a condition that causes progressive vision loss due to photoreceptor degeneration.
Trusts and Foundations
Inherited retinal dystrophies (IRDs) are the leading cause of blindness in working-age people in the UK, and children as young as eighteen-months are regularly diagnosed.
Charities demand increase in benefits
Charities representing blind and partially sighted people are urging the UK Government to increase benefits in line with inflation rather than wages, when a decision is made at the end of the month.
New website aims to increase understanding of genetics
High quality information on genetic testing and counselling for families affected by inherited sight loss is now available in one place thanks to the launch of an innovative new website, Unlock Genetics.
Positive early findings from ProQR trial of USH2A therapy
Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a particular section of the USH2A gene.